Skip to main content

Table 1 Phase I/II clinical trials in oestrogen receptor-positive metastatic breast cancer

From: New targets for therapy in breast cancer: Farnesyltransferase inhibitors

Combination Clinical setting Number of patients Primary end-point Trial group
Tipifarnib + Tamoxifen Hormone responsive/hormone nonresponsive cancer 52 PK/PD National Cancer Institute
Tipifarnib + Tamoxifen Post tamoxifen 40 ORR H Roche (Toulouse)
Tipifarnib + Tamoxifen 2nd line: post tamoxifen or aromatase inhibitor 45 CBR National Cancer Institute
  1. CBR, clinical benefit rate; ORR, objective response rate; PK/PD, pharmacokinetic/pharmacodynamic.